vorinostat
vorinostat: 14 clinical trials tracked.
vorinostat evidence translation
What we can confirm
14 tracked trials
What it means
What to watch
Prepared research question
What is verified about vorinostat, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 5 study sponsors
Related indications
Clinical Trials (14)showing 10 most recent
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Primary endpoint: Objective Tumor Response After One Course of Therapy
Use of Vorinostat as GVHD Prophylaxis in Children, Adolescents, and Young Adults With Non-Malignant Disorders Undergoing Allogeneic Blood and Marrow Transplantation
Primary endpoint: GVHD-free relapse-free Survival
IGHID 12430 - Deliver-02 - A Phase 1, Open Label, Randomized Study To Evaluate The Safety And Tolerability Of MGD014 And MGD020 With A Latency Reversal Agent Versus Temporary Treatment Interruption In Persons With HIV-1 On Antiretroviral Therapy
Primary endpoint: Percent of Participants Experiencing At Least One Grade 3 or Greater Adverse Event that are Possibly or Definitely Related to Study Treatment
Vorinostat to Augment Response to 177Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Primary endpoint: Proportion of patients who convert from prostate-specific membrane antigen (PSMA) low to PSMA high
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Primary endpoint: Minimal Residual Disease
Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Primary endpoint: MTD
A Phase I Study of 131I-MIBG With Dinutuximab +/- Vorinostat for Relapsed/Refractory Neuroblastoma
Primary endpoint: MTD/RP2D Determination Cohort A
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
Primary endpoint: Number of Patients With Grade 3-5 Adverse Events
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Primary endpoint: Event-free survival of ALL patients (EFS)
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Primary endpoint: Percentage of Treatment-related Mortality (TRM)